The National Agency for Food and Drug Administration and Control (NAFDAC) has directed the recall of Embacef 125 Powder for Oral Suspension following confirmed complaints about the product’s quality.
The agency issued a notification to Embassy Pharmaceutical and Chemicals Ltd, Lagos, the registration holder, and Laborate Pharmaceutical India, the manufacturer, after receiving a report at its Ekiti State office that two bottles of the reconstituted suspension caked after the first day of use.
Investigations confirmed poor product quality and safety concerns. As a precaution, NAFDAC has ordered the recall of the affected batch and other potentially compromised batches from circulation.
Embacef 125 Suspension, which contains Cefuroxime Axetil, is an antibiotic used to treat bacterial infections such as bronchitis, gonorrhea, Lyme disease, and infections of the skin, ears, throat, sinuses, tonsils, and urinary tract.
NAFDAC warned that substandard antibiotics pose serious risks, including treatment failure, worsening health conditions, death, and the spread of antibiotic-resistant bacteria.
Healthcare professionals and consumers are urged to report suspected cases of substandard or falsified medicines to the nearest NAFDAC office, call 0800-162-3322, or email sf.alert@nafdac.gov.ng.
